| INTRODUCTION
There are two types of herpes simplex virus (HSV): HSV-1 and HSV-2.
Both viruses cause an initial infection in peripheral tissue followed by the establishment of a latent infection in nervous cells from the regional sensorial ganglia. However, they show different tropism: HSV-1 infects the oral mucosa, causing an orolabial disease, and establishing latency in the trigeminal ganglion; HSV-2 produces a genital disease (genital herpes), establishing latency in the lumbosacral ganglion.
However, the epidemiology of genital herpes seems to have changed in recent years, whereby a significant number of genital infection cases are currently caused by HSV-1. 1 The seroprevalence of both types of HSV differs; for example, in Spanish women, the values of HSV-1 and HSV-2 are, respectively, 78.6% and 3.5%. 2 Thus, the differentiation of type-specific HSV responses is an important issue for clinical laboratories when they attempt to characterize herpes infections. HSV serological diagnosis has for years used antigen extracts of HSV-infected cells, but this approach does not allow type-specific serological responses to be differentiated independently of the virus used to obtain the antigen. 3 Furthermore, the cross-reactivity between HSV-1 and HSV-2 and other herpesviruses, especially VZV, is a serious hindrance to the characterization of the specific serological response. 4 HSV-1 and HSV-2 glycoprotein G (gG; respectively, gG1 and gG2) have been recognized as being type-specific for the corresponding virus, and show good discrimination of antibodies to HSV-1 and HSV-2.
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Serological assays based on the use of gG1 or gG2 as the antigen have been developed to identify type-specific antibodies. 
| MATERIALS AND METHODS
The study included 384 samples, received in the Serology Laboratory of the National Center for Microbiology, for the purpose of examining serology against HSV. Samples were stored at −20°C until use. Finally, the samples were analyzed by IB in an IB device (Profiblot 4B; Tecan, Grödig, Austria). The IB assay determines IgG against a common HSV antigen (native), and gG1 (recombinant, speciesspecific glycoprotein of the Baculovirus system) and gG2 (affinity chromatography-purified species-specific glycoprotein). Samples were tested at 1:101 dilution and identified as being positive for each antigen if they had an intensity greater than those of the gG2 band of a cut-off control included in the kit.
To complete the determination of the serological profile of discrepant samples, HSV-IgG and VZV IgG were assayed by indirect ELISA (Enzygnost; Siemens Healthcare) in a BEP III device.
All serological determinations were carried out following the manufacturer's instructions strictly.
Samples were classified as positive or negative on the basis of a consensus result (at least two coincident positive or negative results with two different techniques).
To calculate sensitivity and specificity of the methods compared, indeterminate results were considered as the most adverse conditions. In other words, when the reference result was negative, an indeterminate result was considered to be positive; conversely, when the reference result was positive, the indeterminate one was considered to be negative.
Statistics were calculated by using Analyse-it version 4.60
(Analyse-it Software, Ltd., Leeds, UK). Kappa statistics were used to cal- 
| RESULTS

| HSV-1
When assayed by IB, 260 samples were positive and 124 were negative. 264 samples gave a positive result with CLIA, one was indeterminate and 119 were negative; when tested by ELISA, 261 samples were positive, 112 were negative and the remaining 11 were indeterminate. A total of 364 samples showed agreement in the three assays, of which 109 had a negative result and 255 had a positive results.
Results from the remaining 20 samples were discrepant (Table 1) .
Four samples were considered unclassifiable, since they gave a different result in each assay (#6, #76, and #9) or an indeterminate result in two assays (#63 
| HSV-2
When assayed by IB 104 samples were positive and 280 were negative. With CLIA, 106 samples gave a positive result, one was indeter- Table 4 
| DISCUSSION
The specific identification of antibodies to HSV-1 and HSV-2 is only possible by means of assays based on the use of type-specific gG.
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Several commercial assays have been developed for testing HSV-1-and HSV-2-specific antibodies. When commercial assays using recombinant antigens were compared with others based on inactivated viral particles, the specificity was improved from 68%-72% to 96% for HSV-1 and from 61%-85% to 100% for HSV-2. 16 and samples from children were used to calculate the specificity. 13, 16, 17 In the present study, we used a con- and HSV-2, and VZV. For HSV-1-discrepant samples, VZV seems to be an important cause of cross-reactivity, as the reactivity to this virus is much higher than that to HSV in other samples (Table 1) . This seems to (Table 1) .
For HSV-2, samples #55 (indeterminate with ELISA) and #36
(positive with CLIA) seem to be caused by cross-reactivity with VZV; in the remaining negative samples with single indeterminate (#146, #181, #90, #92) or positive (#65) results with ELISA, the discrepancies could be explained by cross-reaction between HSV-2 and HSV-1 (Table 3) .
These results strongly suggest that discrepant results with the type-specific methods may be explained on the basis of antigenic cross-reactivity with highly positive IgG VZV samples, as has previously been described, 4, 22 or between HSV-1 and HSV-2.
Another possible explanation for the discrepant results is that inadequate cut-off value was used in the assays. Previous reports suggest that increasing the cut-off of the HSV-2 ELISA used in this study would have improved the specificity of the assay; this seems especially to be the case for samples from sub-Saharan individuals. 24 To explore this further, the results were recalculated considering cut-off values of 3.0 and 3.5 for the ELISA assay. For a cut-off of 3.0, the sensitivity and specificity were 94.7% and 100% (for HSV-1), and 89.6% and 98.9% (HSV-2); for a cut-off of 3.5, the corresponding figures were 93.1% and 100% (HSV-1), and 85.8% and 98.9% (HSV-2). Accordingly, for the HSV-2 assay, the specificity increased slightly (from 97.84% to 98.9%), but the sensitivity was substantially decreased (from 99.06%
to 85.8%; data not shown).
This study was designed to compare the methods for determining HSV-1 and HSV-2 IgG in samples received in a serology context.
Clinical and epidemiological information was not available for most samples, so it was not possible to consider factors that may have affected the characteristics of the tests, such as the presence of acute herpes infection, or the prevalence of some other infections (eg, HIV).
In conclusion, comparing the three methods showed them all to have excellent and comparable performance characteristics for detecting type-specific IgG to HSV-1 and HSV-2. The IB method is advantageous in that it permits the simultaneous determination of HSV-1 and HSV-2 IgG in a single assay, and BIO-FLASH ® has the advantages of a shorter handling time and no requirement to aliquot specimens before assaying them. However, ELISA has the drawback of generating a relatively large number of indeterminate results, making it difficult to characterize samples correctly.
